Savara (SVRA) has drawn fresh attention after shares closed at $4.83, with the stock up about 10% on the day, while longer term returns remain mixed across different time frames.
The recent 10.27% 1 day share price gain to $4.83 comes after a weaker patch, with the 90 day share price return down 17.15% and the year to date move lower by 14.36%, even as Savara’s 1 year total shareholder return of 22.28% and very large 5 year total shareholder return of 327.43% point to a stock where long term holders have been rewarded more than short term traders.
Scan beyond Savara's swing and line up other potential biotech movers with the hand picked 19 high quality undiscovered gems.
Savara just jumped, yet the shares still trade far below analyst targets. Is the discount a genuine opportunity, or a warning that the market has this story right?
Preferred Price-to-Book of 8.5x: Is it justified?
On valuation terms, Savara trades on a P/B ratio of 8.5x, while the shares closed at $4.83, which puts the stock at a premium to the broader US biotech industry and raises questions about how much optimism is already built in.
P/B compares the market value of the equity to its net assets on the balance sheet, so for a clinical stage biopharma group like Savara, it often reflects how investors are weighing the pipeline and future prospects against current losses.
SVRA is described as expensive against the US Biotechs industry average P/B of 1.8x, yet it is framed as good value versus a more concentrated peer group where the average P/B is 21.5x, which suggests the broader market is pricing Savara below some closer comparables while still assigning a much richer tag than the sector overall.
In practical terms, that wide gap cuts both ways for investors, as it indicates strong expectations have already been attached to the Phase 3 asset, but it also signals the stock trades at a discount to peers that carry even higher P/B ratios.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-book ratio of 8.5x (OVERVALUED)
Still, the story can change fast if the Phase 3 molgramostim trial disappoints or if ongoing losses of $139.309 million put pressure on future funding options.
Find out about the key risks to this Savara narrative.
Next Steps
Sentiment on Savara is clearly split, which is exactly why it pays to review the underlying data yourself and pressure test both sides of the story. To weigh up what the market is rewarding and what it is worried about, start with the 1 key reward and 1 important warning sign.
Looking for more investment ideas beyond Savara?
If you only focus on Savara, you could miss other setups that fit your style. Use the Simply Wall St Screener to widen your opportunity set fast.
- Target potential mispricing by scanning a curated 39 high quality undervalued stocks that combines quality fundamentals with attractive valuations before they hit the mainstream.
- Prioritise sleep at night holdings by filtering for a 29 resilient stocks with low risk scores that may better match a cautious approach to capital preservation.
- Strengthen your watchlist with a list of solid balance sheet and fundamentals (24 results) so you are not caught holding companies that struggle when conditions tighten.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com